The FDA was expected to decide on the application of sotorasib and panitumumab for the treatment of metastatic colorectal ...

The regulator has delayed its respective decision dates on whether to grant full approval to Amgen’s Lumakras in metastatic ...

The FDA is looking at four events for the remainder of October, one of which is an advisory committee meeting for a dual SGLT ...

LUMAKRAS, and the newly launched IMDELLTRA. The rare diseases segment also did well. This segment enjoyed a bigger focus after Amgen acquired Horizon Therapeutics. In 2Q24, it achieved more than $ ...

A severe solar storm is headed to Earth that could stress power grids even more as the US deals with disruptions from Hurricane Milton that hit Florida .

Some of its most recent brand-new launches, especially the cancer drug Lumakras, have made paltry (at best) contributions to its top line, while some of its legacy products are racking up ...